Related Experiment Video
Updated: Feb 7, 2026

Generation and Isolation of Cell Cycle-arrested Cells with Complex Karyotypes
Published on: April 13, 2018
CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest
Shom Goel1, Molly J DeCristo2, Sandra S McAllister3
1Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Abstract:
Pharmacologic inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) have recently entered the therapeutic armamentarium of clinical oncologists, and show promising activity in patients with breast and other cancers. Although their chief mechanism of action is inhibition of retinoblastoma (RB) protein phosphorylation and thus the induction of cell cycle arrest, CDK4/6 inhibitors alter cancer cell biology in other ways that can also be leveraged for therapeutic benefit. These include modulation of mitogenic kinase signaling, induction of a senescence-like phenotype, and enhancement of cancer cell immunogenicity. We describe here the less-appreciated effects of CDK4/6 inhibitors on cancer cells, and suggest ways by which they might be exploited to enhance the benefits of these agents for cancer patients.
Insights
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors offer new cancer treatments. Beyond cell cycle arrest, these drugs modify signaling, induce senescence, and boost cancer cell immunogenicity for enhanced therapeutic benefits.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors are emerging therapeutics for various cancers.
- Their primary mechanism involves inhibiting retinoblastoma protein phosphorylation, leading to cell cycle arrest.
Purpose of the Study:
- To explore the less-recognized effects of CDK4/6 inhibitors on cancer cells.
- To identify potential strategies for leveraging these effects to improve patient outcomes.
Main Methods:
- Review of existing literature on CDK4/6 inhibitor mechanisms.
- Analysis of preclinical and clinical data regarding off-target effects.
Main Results:
- CDK4/6 inhibitors modulate mitogenic kinase signaling pathways.
- These agents induce a senescence-like phenotype in cancer cells.
- Enhanced cancer cell immunogenicity is observed with CDK4/6 inhibition.
Conclusions:
- CDK4/6 inhibitors possess multifaceted mechanisms beyond cell cycle arrest.
- Exploiting these additional effects may enhance therapeutic efficacy.
- Further research is warranted to develop combination strategies for improved cancer treatment.
Related Concept Videos
What is the Cell Cycle?
What is the Cell Cycle?
Feedback Inhibition
The Cell Cycle Control System
Cyclins and cyclin-dependent kinases (Cdks) are the primary cell cycle regulators and...
The Cell Cycle Control System
Mitogens and the Cell Cycle

